Goldman Sachs
LEGN icon

Goldman Sachs’s Legend Biotech LEGN Stock Holding History

Goldman Sachs’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.5M Sell
1,464,112
-710,423
-33% -$13.5M ﹤0.01% 2166
2025
Q4 		$47.3M Buy
2,174,535
+1,119,049
+106% +$32.1M 0.01% 1548
2025
Q3 		$34.4M Buy
1,055,486
+113,570
+12% +$4.19M ﹤0.01% 1743
2025
Q2 		$33.4M Sell
941,916
-11,915
-1% -$386K ﹤0.01% 1656
2025
Q1 		$32.4M Sell
953,831
-1,538,840
-62% -$55.2M 0.01% 1576
2024
Q4 		$81.1M Buy
2,492,671
+2,035,727
+446% +$84.3M 0.01% 931
2024
Q3 		$22.3M Sell
456,944
-211,046
-32% -$11.2M ﹤0.01% 1967
2024
Q2 		$29.6M Buy
667,990
+357,582
+115% +$16.5M 0.01% 1545
2024
Q1 		$17.4M Sell
310,408
-212,259
-41% -$12.8M ﹤0.01% 1962
2023
Q4 		$31.4M Buy
522,667
+260,899
+100% +$16.5M 0.01% 1517
2023
Q3 		$17.6M Sell
261,768
-127,433
-33% -$8.85M ﹤0.01% 1922
2023
Q2 		$26.9M Buy
389,201
+133,215
+52% +$8.7M 0.01% 1593
2023
Q1 		$12.3M Buy
255,986
+49,583
+24% +$2.43M ﹤0.01% 2224
2022
Q4 		$10.3M Sell
206,403
-350,255
-63% -$17M ﹤0.01% 2561
2022
Q3 		$22.7M Buy
556,658
+138,330
+33% +$6.49M 0.01% 1758
2022
Q2 		$23M Buy
418,328
+51,464
+14% +$2.17M 0.01% 1783
2022
Q1 		$13.3M Buy
366,864
+147,830
+67% +$5.84M ﹤0.01% 2401
2021
Q4 		$10.2M Buy
219,034
+144,190
+193% +$7.31M ﹤0.01% 2741
2021
Q3 		$3.78M Buy
74,844
+21,087
+39% +$877K ﹤0.01% 3593
2021
Q2 		$2.21M Buy
53,757
+45,395
+543% +$1.54M ﹤0.01% 4111
2021
Q1 		$243K Sell
8,362
-6,121
-42% -$167K ﹤0.01% 5548
2020
Q4 		$408K Buy
+14,483
New +$417K ﹤0.01% 4731

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs's LEGN Position: Q1 2026 in Review

Goldman Sachs reduced its Legend Biotech (LEGN) stake by 33% in Q1 2026, selling an estimated $13.5M and leaving 1,464,112 shares worth $26.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2166.

Goldman Sachs first reported a position in LEGN in Q4 2020 and has held it in 22 quarters since. The position peaked at $81.1M in Q4 2024. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Goldman Sachs held 1,464,112 shares of Legend Biotech worth $26.5M as of Q1 2026.
  • Goldman Sachs sold 710,423 Legend Biotech shares in Q1 2026, an estimated $13.5M.
  • Legend Biotech made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2166 holding.
  • Goldman Sachs first reported a position in Legend Biotech in Q4 2020 and has held it in 22 quarters since.
  • Goldman Sachs's Legend Biotech position peaked at $81.1M in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.